Journal of Hepatology
Volume 51, Issue 3 , Pages 475-482 , September 2009

The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome

Received 18 December 2008 ,Revised 6 March 2009 ,Accepted 6 April 2009.

References 

  1. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac , et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46:1872–1882
  2. Plessier A, Denninger M-H, Consigny Y, Pessione F, Francoz C, Durand F, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int. 2003;23:440–448
  3. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Sem Liver Dis. 2002;22:83–96
  4. Tandon P, Garcia-Tsao G. Bacterial infection, sepsis, and multiorgan failure in cirrhosis. Sem Liver Dis. 2008;28:26–42
  5. Lach L, Gines P, Arroyo V, Rimola A, Titò L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroeneterology. 1988;94:482–487
  6. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med. 2005;31:1693–1699
  7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Chest. 1992;101:1644–1655
  8. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000;32:142–153
  9. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases, 4th ed. New York: Churchill Livingstone, 1995:662–90.
  10. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223–229
  11. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649
  12. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Thernau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470
  13. Atterbury CE, Maddrey WC, Conn H. Neomicin–sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled. Double-blind clinical trial. Am J Dig Dis. 1978;23:398–406
  14. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167–176
  15. Arroyo V, Gines P, Gerbes A, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164–176
  16. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56:1310–1318
  17. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001;33:41–48
  18. Navasa M, Rodes J. Bacterial infections in cirrhosis. Liver Int. 2004;24:277–280
  19. Wilkinson SP, Arroyo V, Gazzard BG, Monodie H, Williams R. Relation of renal impairment and hemorrhagic diathesis to endotoxemia in fulminant hepatic failure. Lancet. 1974;1:521–524
  20. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taura P, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol. 2001;34:32–37
  21. Albillos A, de la Hera A, Gonzales M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysoccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37:208–217
  22. Albillos A, de la Hera A, Reyes E, Monserrat J, Munoz L, Nieto M, et al. Tumor necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol. 2004;40:624–631
  23. Zapater P, Francés R, González-Navajas JM, de la Hoz MA, Moreau R, Pascual S, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology. 2008;48:1924–1931
  24. Bolognesi M, Merkel C, Bianco S, Angeli P, Sacerdoti D, Amodio P, et al. Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology. 1994;19:628–634
  25. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA. 1995;274:58–65
  26. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-α production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol. 2006;45:280–289
  27. Navasa M, Follo A, Filella X, Jimenez W, Francitorra A, Planas R, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal failure and mortality. Hepatology. 1998;27:1227–1232
  28. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409
  29. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet. 1999;353:139–142
  30. Vaquero J, Polson J, Chung C, Helenowsky I, Schiodt FV, Reisch J, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125:755–764
  31. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247–254
  32. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32:734–739
  33. Jalan R, Pollok A, Shah S, Medhavan K, Simpson K. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol. 2002;37:536–538
  34. Afessa B, Kubilis PS. Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol. 2000;95:484–489
  35. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao L, et al. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut. 2005;54:718–725
  36. Sen S, Mookerjee RP, Cheshire LM, Davies NA, WilliamsR , Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol. 2005;43:142–148
  37. Donati G, Piscaglia F, Coli L, Silvagni E, Righini R, Donati G, et al. Acute systemic, splanchnic and renal hemodynamic changes induced by molecular adsorbent recirculating system (MARS) treatment in patients with end-stage cirrhosis. Aliment Pharmacol Ther. 2007;26:717–726

☆ The authors declared that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00371-7

doi: 10.1016/j.jhep.2009.04.017

Journal of Hepatology
Volume 51, Issue 3 , Pages 475-482 , September 2009

Article Tools

* Image Usage & Resolution